TWST — Twist Bioscience Balance Sheet
0.000.00%
- $1.70bn
- $1.45bn
- $312.97m
- 78
- 27
- 25
- 38
Annual balance sheet for Twist Bioscience, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 290 | 478 | 505 | 336 | 276 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 26.4 | 28.5 | 40.3 | 44.1 | 34.9 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 335 | 546 | 596 | 424 | 347 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 59.2 | 106 | 214 | 203 | 161 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 399 | 702 | 961 | 776 | 614 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 36 | 63.1 | 90.7 | 73.3 | 71 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 62.6 | 121 | 172 | 153 | 142 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 336 | 581 | 789 | 623 | 473 |
| Total Liabilities & Shareholders' Equity | 399 | 702 | 961 | 776 | 614 |
| Total Common Shares Outstanding |